STOK
Stoke Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.82
+2.69%Year over year
Reported trailing growth
- Revenue
- -86.2%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +6.2%
- EBITDA
- -22.7%
- EPS
- -15.6%
Three-year CAGR
- Revenue
- +145.9%
- EBITDA
- +94.1%
- EBIT
- +79.7%
- Net income
- +92.3%
- EPS
- +92.7%
- Free cash flow
- +151.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026